Results 131 to 140 of about 6,725 (159)

NIRAPARIB SALTS

2020
STEWART ALISTAIR JAMES, WANG YI, WU GEORGE, YIN JIANGUO   +3 more
openaire   +4 more sources

Real-World Safety and Effectiveness of Maintenance Niraparib for Platinum-Sensitive Recurrent Ovarian Cancer: A GEICO Retrospective Observational Study Within the Spanish Expanded-Access Programme

European Journal of Cancer, 2023
María Teresa Martín Gómez, Antonio González-Martín, Luisa Sanchez-Lorenzo   +2 more
exaly  

A Novel Combination of Niraparib and Anlotinib in Platinum-Resistant Ovarian Cancer: Efficacy and Safety Results From the Phase II, Multi-Center ANNIE Study

EClinicalMedicine, 2022
Guo-Chen Liu, Jihong Liu, Chuyao Zhang
exaly  

Niraparib

2018
Tesch, Hans, Lüftner, Diana, Wörmann, Bernhard, Deutsche Gesellschaft Für Hämatologie Und Medizinische Onkologie, Deutschland. Gemeinsamer Bundesausschuss   +4 more
openaire   +1 more source

Niraparib/pembrolizumab

Reactions Weekly, 2021
openaire   +1 more source

NIRAPARIB FORMULATIONS

2019
MCGURK SIMON, NARAYAN PADMA, RAJLIC ALEKSANDAR   +2 more
openaire   +2 more sources

Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer

New England Journal of Medicine, 2019
Roisin E. O'Cearbhaill, Antonio González-Martín, Andres Redondo Sanchez   +2 more
exaly  

Determination of Interactions Between Human Serum Albumin and Niraparib Through Multi-Spectroscopic and Computational Methods

Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2019
Di Wu, Peixiao Tang, Qiaomei Sun
exaly  

Long-Term Safety in Patients With Recurrent Ovarian Cancer Treated With Niraparib Versus Placebo: Results From the Phase III ENGOT-OV16/NOVA Trial

Gynecologic Oncology, 2020
Jørn Herrstedt, Jonathan A Ledermann, D Berton-Rigaud   +2 more
exaly  

Niraparib/nivolumab

Reactions Weekly, 2022
openaire   +1 more source